Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Revenue of Neuronetics, Inc. (STIM)
Revenue in 2023 (TTM): $71.35 M
According to Neuronetics, Inc.'s latest financial reports the company's current revenue (TTM) is $71.35 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Neuronetics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $71.35 M | $51.71 M | $-22,759,000 | $-30,189,000 | $-30,189,000 |
| 2022 | $65.21 M | $49.72 M | $-31,260,000 | $-37,159,000 | $-39,207,000 |
| 2021 | $55.31 M | $43.66 M | $-26,554,000 | $-31,193,000 | $-35,602,000 |
| 2020 | $49.24 M | $37.69 M | $-21,066,000 | $-27,453,000 | $-32,277,000 |
| 2019 | $62.66 M | $47.27 M | $-26,930,000 | $-29,044,000 | $-34,300,000 |
| 2018 | $52.78 M | $40.33 M | $-19,527,000 | $-24,097,000 | $-24,097,000 |
| 2017 | $40.43 M | $30.8 M | $-12,578,000 | $-16,059,000 | $-16,059,000 |
| 2016 | $34.23 M | $27.61 M | $-8,726,000 | $-11,234,000 | $-11,234,000 |